Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Forecast: Value Set To Climb From $1.22 Billion To $2.12 Billion
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size has witnessed rapid growth in recent years. It is anticipated to expand from $1.06 billion in 2025 to $1.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. The historical increase can be attributed to several factors, including an increase in cervical cancer screening program coverage, the adoption of molecular diagnostics in gynecology, a rising awareness of hr-hpv infection risks, the availability of automated pcr platforms, and the expansion of centralized diagnostic laboratories.
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $2.12 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.9%. This projected growth during the forecast period is fueled by factors such as a greater emphasis on primary HPV screening, a rising need for highly specific cancer risk assessment, the expansion of screening initiatives across populations, the incorporation of digital pathology and reporting platforms, and increased capital directed towards precision diagnostics. Key developments expected within this period encompass the wider acceptance of mRNA-based primary cervical screening methods, an increase in the utilization of fully automated molecular testing equipment, a growing trend towards incorporating genotype-specific reflex testing, the development of more precise screening algorithms, and a heightened emphasis on identifying clinically significant HPV infections.
Get A Free Sample Report With In-Depth Market Insights:
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Industry Drivers: What’s Behind The Revenue Growth?
The rising prevalence of cervical cancer is anticipated to drive the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market. Cervical cancer is a malignant disease originating in the cells of the cervix, primarily caused by persistent high-risk human papillomavirus infections, and it is a major global contributor to cancer-related illness and mortality among women. The increasing occurrence of cervical cancer is often attributed to low participation in cervical screening, which leads to delayed diagnosis and the advancement of persistent human papillomavirus infections into cancer. Cervical human papillomavirus messenger ribonucleic acid testing assists in identifying active high-risk human papillomavirus infections, thereby improving risk stratification and facilitating timely interventions to slow the progression of cervical cancer. As an illustration, in December 2025, Cancer Australia, an Australia-based Government Agency, reported 265 deaths from cervical cancer in Australia in 2023, with an estimated 254 deaths projected for 2025. Thus, the increasing prevalence of cervical cancer is a significant factor boosting the growth of the cervical human papillomavirus messenger ribonucleic acid testing market.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Segment Analysis: What Are The Core Market Categories?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market covered in this report is segmented –
1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
2) By Application: Cervical Cancer Screening; Research; Other Applications
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
#Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies operating in the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are focusing on advancing technology, such as multiplex real-time PCR innovations, to gain a competitive advantage. This includes improving diagnostic accuracy, allowing for simultaneous E6/E7 mRNA detection and high-risk HPV genotyping, minimizing false positives, lowering testing costs, and increasing adoption. Multiplex real-time PCR innovations enable the detection and quantification of multiple HPV E6/E7 mRNA targets and high-risk genotypes concurrently in one PCR reaction, thereby enhancing the accuracy, efficiency, and clinical relevance of cervical HPV testing. As an illustration, in July 2024, Medicon Hellas S.A., a Greece-based diagnostics company, launched a multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping, acting as the exclusive distributor for uni-medica in Greece and Cyprus. This kit is compatible with various PCR instruments like the bio-rad cfx96 and hongshi slan-96 series for fluorochrome analysis with ct values, can be used with diverse samples including semen, urine, and anal swabs in addition to cytology, and possesses CE-IVD marking, delivering results in 2.5 hours.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.
View The Full Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Report:
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
